![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Generalised additive model analysis of the relationship between darunavir pharmacokinetics and pharmacodynamics following once-daily darunavir/ ritonavir 800/100mg treatment in the Phase III trials, ARTEMIS and ODIN
|
|
|
Reported by Jules Levin
Glasgow 2012 Nov 11-15
Thomas N Kakuda,1 Frank Tomaka,1 Tom Van De Casteele,2 Tony Vangeneugden2
1Janssen Research & Development, LLC, Titusville, NJ, USA; 2Janssen Infectious Diseases BVBA, Beerse, Belgium
![AASLD1.gif](../images/112612/112612-11/AASLD1.gif)
![AASLD2.gif](../images/112612/112612-11/AASLD2.gif)
![AASLD3.gif](../images/112612/112612-11/AASLD3.gif)
![AASLD4.gif](../images/112612/112612-11/AASLD4.gif)
![AASLD5.gif](../images/112612/112612-11/AASLD5.gif)
![AASLD6.gif](../images/112612/112612-11/AASLD6.gif)
![AASLD7.gif](../images/112612/112612-11/AASLD7.gif)
![AASLD8.gif](../images/112612/112612-11/AASLD8.gif)
![AASLD9.gif](../images/112612/112612-11/AASLD9.gif)
![AASLD10.gif](../images/112612/112612-11/AASLD10.gif)
![AASLD11.gif](../images/112612/112612-11/AASLD11.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|